company background image

Pfizer NYSE:PFE Stock Report

Last Price


Market Cap







12 Aug, 2022


Company Financials +
PFE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance6/6
Financial Health6/6

PFE Stock Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

Pfizer Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pfizer
Historical stock prices
Current Share PriceUS$50.11
52 Week HighUS$61.71
52 Week LowUS$40.94
1 Month Change-3.24%
3 Month Change0.38%
1 Year Change3.36%
3 Year Change44.62%
5 Year Change53.38%
Change since IPO1,593.86%

Recent News & Updates

Aug 11

Pfizer involvement in Zantac woes 'smaller than people think' - Wells Fargo

A decline in Pfizer's (NYSE:PFE) share price today is "unwarranted" as the company's exposure to litigation regarding the heartburn drug Zantac "may be smaller than people think," according to Wells Fargo. Analyst Mohit Bansal said "Overall, we think the weakness in PFE stock appears unwarranted as their liability may be minimal if any from our understanding." In April 2020, the U.S. FDA requested over-the-counter Zantac (ranitidine) and its generics be removed from the market after finding it is linked to unacceptable levels of the potential human carcinogen, N-nitrosodimethylamine. Drugmakers Sanofi (SNY), GlaxoSmithKline (GSK), and Haleon (HLN) are under pressure Thursday due to potential legal exposure.

Shareholder Returns

PFEUS PharmaceuticalsUS Market

Return vs Industry: PFE exceeded the US Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: PFE exceeded the US Market which returned -11.7% over the past year.

Price Volatility

Is PFE's price volatile compared to industry and market?
PFE volatility
PFE Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.

About the Company

184979,000Albert Bourla

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.

Pfizer Inc. Fundamentals Summary

How do Pfizer's earnings and revenue compare to its market cap?
PFE fundamental statistics
Market CapUS$281.23b
Earnings (TTM)US$29.48b
Revenue (TTM)US$101.28b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PFE income statement (TTM)
Cost of RevenueUS$37.72b
Gross ProfitUS$63.56b
Other ExpensesUS$34.07b

Last Reported Earnings

Jul 03, 2022

Next Earnings Date


Earnings per share (EPS)5.25
Gross Margin62.75%
Net Profit Margin29.11%
Debt/Equity Ratio46.3%

How did PFE perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio